The relationship of premature mitosis to cytotoxicity in response to checkpoint abrogation and antimetabolite treatment.
about
Trial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapyStructure-based design, discovery and development of checkpoint kinase inhibitors as potential anticancer therapiesCHD7 expression predicts survival outcomes in patients with resected pancreatic cancer.Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair.Checkpoint signaling, base excision repair, and PARP promote survival of colon cancer cells treated with 5-fluorodeoxyuridine but not 5-fluorouracil.Inhibition of checkpoint kinase 2 (CHK2) enhances sensitivity of pancreatic adenocarcinoma cells to gemcitabineCombined inhibition of Wee1 and PARP1/2 for radiosensitization in pancreatic cancer.Inhibition of protein phosphatase 2A radiosensitizes pancreatic cancers by modulating CDC25C/CDK1 and homologous recombination repairAssessment of chk1 phosphorylation as a pharmacodynamic biomarker of chk1 inhibition.Comparative analysis of radiosensitizers for K-RAS mutant rectal cancersPoly(ADP-Ribose) polymerase inhibition synergizes with 5-fluorodeoxyuridine but not 5-fluorouracil in ovarian cancer cells.Enhancement of hypoxia-activated prodrug TH-302 anti-tumor activity by Chk1 inhibition.Selective radiosensitization of p53 mutant pancreatic cancer cells by combined inhibition of Chk1 and PARP1.Sensitization of pancreatic cancer stem cells to gemcitabine by Chk1 inhibition.Poly(ADP-ribose) polymerase 1 modulates the lethality of CHK1 inhibitors in mammary tumors.Sensitization of Pancreatic Cancers to Gemcitabine Chemoradiation by WEE1 Kinase Inhibition Depends on Homologous Recombination RepairCCT244747 is a novel potent and selective CHK1 inhibitor with oral efficacy alone and in combination with genotoxic anticancer drugs.Dissociation of gemcitabine chemosensitization by CHK1 inhibition from cell cycle checkpoint abrogation and aberrant mitotic entry.CCT241533 is a potent and selective inhibitor of CHK2 that potentiates the cytotoxicity of PARP inhibitors.Improving gemcitabine-mediated radiosensitization using molecularly targeted therapy: a reviewSelective tumor killing based on specific DNA-damage response deficiencies.Hypoglycemic/hypoxic condition in vitro mimicking the tumor microenvironment markedly reduced the efficacy of anticancer drugs.Cisplatin-induced DNA damage activates replication checkpoint signaling components that differentially affect tumor cell survival.Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells.Multicellular tumor spheroid model to evaluate spatio-temporal dynamics effect of chemotherapeutics: application to the gemcitabine/CHK1 inhibitor combination in pancreatic cancerEnhancing CHK1 inhibitor lethality in glioblastoma.Suppression of the FA pathway combined with CHK1 inhibitor hypersensitize lung cancer cells to gemcitabine.Inhibition of CHK1 sensitizes Ewing sarcoma cells to the ribonucleotide reductase inhibitor gemcitabine.PARP1 Trapping and DNA Replication Stress Enhance Radiosensitization with Combined WEE1 and PARP Inhibitors.Structure-based quantitative structure-activity relationship studies of checkpoint kinase 1 inhibitors.
P2860
Q26745686-F0C303F3-7E21-4F26-9C77-44200FB07365Q26864870-E2AD1A11-3EB6-41F4-8C52-F3852D958398Q33630872-DD4A5900-116C-43CC-998D-56BADCFE1230Q33926817-1D170898-11AD-48A7-A2EC-FDDDCFB7EA2EQ34110442-5F555592-D267-4A6D-9C39-7EF506DBFDA6Q34154791-7F2EF76A-89AF-42FB-9066-B6B7B3E649DFQ34287982-319ED2EF-4298-4E4B-91CF-1841B8ECC1E3Q34777845-E95E13E7-5C4F-434C-8D75-4D0CD68FC275Q35023976-3A55793A-D80F-4110-9959-221EE43261D3Q35070685-01093F1C-3A79-45D9-B6C7-4757DB975EAFQ35112912-1A5201E9-7914-46CF-BDCA-BF1D825A590AQ35637224-D67B60FD-37C0-4C3A-AF2F-AA10041EEED7Q35737519-5CC84003-1F78-425C-AD81-0358A5184CDFQ36088183-654034FF-83C2-4D00-9576-129DA80DB29AQ36105500-29D460E9-24C2-4364-AB99-E01464F8D320Q36309585-577C8065-E498-4D5C-A5AA-61F5DF4E707BQ36328196-38219FDB-270D-471B-B6F3-E65F4A2AD82FQ36838392-2C6E530D-9D9C-4E54-A339-E83FAA8EB5C7Q37103465-756784D8-6D41-4D64-8543-EADBF7EA0B83Q37230970-9E754D4F-B03F-4C05-959D-54F63659B524Q37976982-616FD5E5-8C47-4FF8-B0E1-FD6DDDA42379Q39604676-D37A1EF3-21BB-4E86-8752-F202B9BFF429Q39858700-22C244B7-FEA9-4A0B-982D-68AB9AFB306EQ39896274-5EA6E740-BFF9-4846-A5EE-E6A70DE2D28DQ41145824-E93960D0-3214-49D9-A301-487C5BCA2C30Q41767263-AF26576F-5730-452A-A10A-8BDD07795A37Q43973311-2C090FD6-C63C-4302-82DE-08717F416A10Q47130816-C364C071-DC59-4174-8153-3735D1633B25Q47604328-56E396C0-EA39-48AF-BF45-1E92561B250FQ51661462-AD04E730-1129-469B-BD8A-1C54F683A804
P2860
The relationship of premature mitosis to cytotoxicity in response to checkpoint abrogation and antimetabolite treatment.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
The relationship of premature ...... and antimetabolite treatment.
@en
type
label
The relationship of premature ...... and antimetabolite treatment.
@en
prefLabel
The relationship of premature ...... and antimetabolite treatment.
@en
P2093
P356
P1433
P1476
The relationship of premature ...... and antimetabolite treatment.
@en
P2093
Jonathan Maybaum
Joshua D Parsels
Leslie A Parsels
Meredith A Morgan
Theodore S Lawrence
P304
P356
10.4161/CC.5.17.3184
P577
2006-09-01T00:00:00Z